Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Status:
Terminated
Trial end date:
2017-10-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior
to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing
another person's hematopoietic stem cells (bone marrow transplantation) will be successful in
people who have advanced primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis
(PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as
myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites
because the bone marrow itself undergoes fibrosis or scarring. This study plans to evaluate
whether adding the drug Ruxolitinib will further aid in reducing pre-transplant spleen size,
improve physical performance levels and reduce adverse events (side effects) related to the
transplant. Ruxolitinib is a drug that is approved by the FDA for the treatment of patients
with advanced forms of myelofibrosis. Using Ruxolitinib prior to stem cell transplantation is
experimental.
Phase:
Phase 2
Details
Lead Sponsor:
John Mascarenhas
Collaborators:
Incyte Corporation Myeloproliferative Disorders-Research Consortium National Cancer Institute (NCI) Novartis